Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance

NCT00752479 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Necessity of major revision of the protocol

Conditions

Kidney Transplant

Interventions

BIOLOGICAL: Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil
DRUG: Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil

Sponsor

Mario Negri Institute for Pharmacological Research